

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

Claims 1-12. (Canceled)

Claim 13. (Currently Amended) A method of inhibiting lymphocyte activation without killing lymphocytes, comprising[[,]] administering to a patient in need thereof an antibody that binds to a protein having an amino acid sequence as set forth in SEQ ID NO: 1.

Claim 14. (Withdrawn) A method according to claim 13, wherein the lymphocytes are T cells.

Claim 15. (Previously Presented) A method according to claim 13, wherein the lymphocytes are B cells.

Claim 16. (Previously Presented) A method according to claim 13, wherein the antibody is a monoclonal antibody.

Claim 17. (Previously Presented) A method according to claim 16, wherein the antibody comprises a constant region of human antibody.

Claim 18. (Previously Presented) A method according to claim 16, wherein the antibody is a chimeric antibody or humanized antibody.

Claim 19. (Previously Presented) A method according to claim 16, wherein the antibody is an anti-HM1.24 antibody.

Claim 20. (Previously Presented) A method according to claim 18, wherein the antibody is a chimeric anti-HM1.24 antibody.

Claim 21. (Previously Presented) A method according to claim 18, wherein the antibody is a humanized anti-HM1.24 antibody.

- Claim 22. (Previously Presented) A method according to claim 1, wherein the antibody binds to an epitope recognized by an anti-HM1.24 antibody.
- Claim 23. (Previously Presented) A method of treating a disease associated with lymphocyte activation comprising, administering to a patient in need thereof an antibody that binds to a protein having an amino acid sequence as set forth in SEQ ID NO: 1.
- Claim 24. (Previously Presented) A method according to claim 23, wherein said disease is selected from the group consisting of autoimmune disease, rejection in organ transplantation, and allergy.